Tudor Oprea
Tudor Oprea
CEO, Expert Systems Inc
Verified email at - Homepage
Cited by
Cited by
A comprehensive map of molecular drug targets
R Santos, O Ursu, A Gaulton, AP Bento, RS Donadi, CG Bologa, ...
Nature reviews Drug discovery 16 (1), 19-34, 2017
The design of leadlike combinatorial libraries
SJ Teague, AM Davis, PD Leeson, T Oprea
Angewandte Chemie International Edition 38 (24), 3743-3748, 1999
Is There a Difference Between Leads and Drugs? A Historical Perspective.
TI Oprea, AM Davis, SJ Teague, PD Leeson
Journal of chemical information and computer sciences 41 (5), 1308-1315, 2001
Virtual and biomolecular screening converge on a selective agonist for GPR30
CG Bologa, CM Revankar, SM Young, BS Edwards, JB Arterburn, ...
Nature chemical biology 2 (4), 207-212, 2006
Property distribution of drug-related chemical databases
TI Oprea
Journal of computer-aided molecular design 14, 251-264, 2000
BDDCS, the Rule of 5 and drugability
LZ Benet, CM Hosey, O Ursu, TI Oprea
Advanced drug delivery reviews 101, 89-98, 2016
Estrogen signaling through the transmembrane G protein–coupled receptor GPR30
ER Prossnitz, JB Arterburn, HO Smith, TI Oprea, LA Sklar, HJ Hathaway
Annu. Rev. Physiol. 70 (1), 165-190, 2008
BDDCS applied to over 900 drugs
LZ Benet, F Broccatelli, TI Oprea
The AAPS journal 13, 519-547, 2011
Pursuing the leadlikeness concept in pharmaceutical research
MM Hann, TI Oprea
Current opinion in chemical biology 8 (3), 255-263, 2004
QSAR without borders
EN Muratov, J Bajorath, RP Sheridan, IV Tetko, D Filimonov, V Poroikov, ...
Chemical Society Reviews 49 (11), 3525-3564, 2020
In vivo effects of a GPR30 antagonist
MK Dennis, R Burai, C Ramesh, WK Petrie, SN Alcon, TK Nayak, ...
Nature chemical biology 5 (6), 421-427, 2009
Distribution and characterization of estrogen receptor G protein-coupled receptor 30 in the rat central nervous system
E Brailoiu, SL Dun, GC Brailoiu, K Mizuo, LA Sklar, TI Oprea, ER Prossnitz, ...
Journal of endocrinology 193 (2), 311-321, 2007
G protein–coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17β-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells
L Albanito, A Madeo, R Lappano, A Vivacqua, V Rago, A Carpino, ...
Cancer research 67 (4), 1859-1866, 2007
Chemography: the art of navigating in chemical space
TI Oprea, J Gottfries
Journal of combinatorial chemistry 3 (2), 157-166, 2001
Temporal disease trajectories condensed from population-wide registry data covering 6.2 million patients
AB Jensen, PL Moseley, TI Oprea, SG Ellesøe, R Eriksson, H Schmock, ...
Nature communications 5 (1), 4022, 2014
Integrating virtual screening in lead discovery
TI Oprea, H Matter
Current opinion in chemical biology 8 (4), 349-358, 2004
Unexplored therapeutic opportunities in the human genome
TI Oprea, CG Bologa, S Brunak, A Campbell, GN Gan, A Gaulton, ...
Nature reviews Drug discovery 17 (5), 317-332, 2018
VALIDATE: A new method for the receptor-based prediction of binding affinities of novel ligands
RD Head, ML Smythe, TI Oprea, CL Waller, SM Green, GR Marshall
Journal of the American Chemical society 118 (16), 3959-3969, 1996
Drug repurposing from an academic perspective
TI Oprea, JE Bauman, CG Bologa, T Buranda, A Chigaev, BS Edwards, ...
Drug Discovery Today: Therapeutic Strategies 8 (3-4), 61-69, 2011
Novel chemical space exploration via natural products
J Rosén, J Gottfries, S Muresan, A Backlund, TI Oprea
Journal of medicinal chemistry 52 (7), 1953-1962, 2009
The system can't perform the operation now. Try again later.
Articles 1–20